The TERZO study evaluates Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma, lacking a standard treatment. The trial compares Copiktra with Gemzar or Bendeka, focusing on ...
MB-105, a CD5-targeted CAR-T cell therapy, has received FDA regenerative medicine advanced therapy designation for relapsed/refractory CD5-positive T-cell lymphoma. The designation aims to expedite ...
When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to treatment for some patients, with its high end durable response rates, and ...
Researchers developed CAR T cells targeting uPAR to attack both tumor cells and supportive microenvironment cells. The ...
Epigenetic drugs boost CD20/CD19 and T-cell activity, making bispecific antibodies hit lymphoma harder—now moving into ...
CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...
Lymph nodes are key control centers in the immune system and play an important role in defending the body against infections ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results